Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Conditions: Hepatocellular Carcinoma; Radiotherapy; Tislelizumab; Tumor Thrombosis Interventions: Radiation: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy; Drug: Tislelizumab Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Cancer | Cancer & Oncology | Carcinoma | China Health | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research | Study | Thrombosis